Document is current
Any future updates will be listed below
-
Authors
Radenkovic, Silvia https://orcid.org/0000-0001-8190-7736
Preston, Graeme
Budhraja, Rohit
Muffels, Irena
Ligezka, Anna
Staff, Nathan P.
Hrstka, Ron
Balakrishnan, Bijina
Shah, Rameen
Verberkmoes, Sanne
Shammas, Ibrahim
Bosnyak, Inez
Stiers, Kyle M.
Lai, Kent
Beamer, Lesa J.
Pandey, Akhilesh
Morava, Eva
Kozicz, Tamas
-
Funding
Funding for this research was provided by:
University of Pécs
- License Information
-
More Information
Article History
Received: 9 July 2025
Accepted: 30 January 2026
First Online: 21 February 2026
Declarations
:
: Informed research consent was obtained from all patients included in this study. Deidentified, residual samples from PGM1-CDG affected individual were used to create hiPSCs. hiPSC cell lines were derived from fibroblasts previously collected as part of clinical management and evaluation and stored in the Frontiers of Congenital Disorders of Glycosylation (FCDGC) biobank at Mayo Clinic (Mayo Clinic IRB: 16-004682) in accordance with the declaration of Helsinki. Additional healthy fibroblasts were obtained from Coriell institute (GM01651, GM08399). Two hiPSC cell lines (1363, 8858) were a gift from Dr. Sergiu Pasca and previously reported [20]. Demographic and genetic information of the PGM1-CDG individuals whose cell lines were used is given in Table .
: Authors have no conflicts of interest to declare.
